ArticleFrontiers in pharmacology2026
Targeting Nox4 alleviates TMJ osteoarthritis by restoring redox homeostasis and suppressing ferroptosis in macrophages.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Temporomandibular osteoarthritis (TMJ OA) is a degenerative disease with pain, abnormal sound, and restricted mouth - opening. Oxidative stress and ferroptosis contribute to its progression, and inflammatory macrophages in the synovium are crucial. Nicotinamide adenine dinucleotide phosphate (NADPH) oxidase 4 (Nox4), a major Reactive Oxygen Species (ROS) source, is involved in joint disorders, but the mechanism of Nox4 regulating macrophage ferroptosis in TMJ OA is unclear. Method: RNA-sequencing was performed on synovial tissues obtained from patients or rats with or without TMJ OA to identify potential therapeutic targets for TMJ OA. Synovial tissues were examined histologically after staining with immunofluorescence. The impact of silencing Nox4 gene expression on inflammatory macrophages was explored. RT-qPCR and Western blotting were used to evaluate the expression of inflammatory and antioxidant genes. Intracellular and mitochondrial ROS were detected using DCFH-DA, DHE, or MitoSOX probes. Mitochondrial membrane potential was detected using the JC-1 probe. Lipid peroxidation and ferroptosis were measured using C11-BODIPY and FerroOrange. RNA-seq was used to analyze the anti-inflammatory mechanisms of the Nox4 inhibitor GLX351322 (40 μM) in LPS-stimulated macrophages. Results: In this study, we observed a marked upregulation of Nox4 expression in synovial macrophages from both TMJ OA patients and rats. Inhibition of Nox4 significantly attenuated inflammatory responses through activation of the nuclear factor erythroid 2-related factor 2 (Nrf2) pathway. Upon inhibition of Nox4, ROS production was reduced, accompanied by a reduction in mitochondrial damage. Meanwhile, Nox4 inhibition decreased ferroptosis in inflammatory macrophages by mitigating oxidative stress-induced lipid peroxidation. Conclusion: In this study, we identified Nox4 as a potential therapeutic target in TMJ OA. Targeting Nox4 counld reduce macrophage inflammation by alleviating oxidative stess-induced ferroptosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.